J Korean Diabetes.
2011 Dec;12(4):190-193. 10.4093/jkd.2011.12.4.190.
Use of Oral Hypoglycemic Agents in Type 2 Diabetic Patients with Hepatic Dysfunction
- Affiliations
-
- 1Devision of Endocrinology and Metabolism, Department of Internal Medicine, Gachon University School of Medicine, Incheon, Korea. ylee@gilhospital.com
- KMID: 2059849
- DOI: http://doi.org/10.4093/jkd.2011.12.4.190
Abstract
- The prevalence of type 2 diabetes mellitus in the Korea has increased dramatically over the past decade. Clinicians can prescribe the following six currently available classes of oral hypoglycemic agents: sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors and dipeptidyl peptidase inhibitors. The availability of various oral hypoglycemic agents has given rise to several adverse effects and may result in worse outcomes in patients with comorbid conditions such as liver dysfunction, renal impairment and heart failure. When taking a cross-sectional view of hepatic dysfunction, we find that hepatitis B and alcoholic liver disease are most prevalent in Korea. The use of oral hypoglycemic agents in type 2 diabetic patients with hepatic dysfunction requires many considerations.
MeSH Terms
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Clinical Practice Guideline 2015: Oral Hypoglycemic Agents for Patients with Type 2 Diabetes
- Oral Antidiabetic Agents in Patients with Chronic Kidney Disease
- Fetal Organogenesis in a Pregestational Diabetic Mother Who has Taking an Oral Hypoglycemic Agent in Early Pregnancy
- Glycemic Control in Diabetic Patients with Diabetic Nephropathy
- A Pregnant Woman with Type 2 Diabetes Unintentionally Exposed to Metformin and Voglibose until the Second Trimester of Pregnancy: A Case Report
